thalidomide has been researched along with Behavior Disorders in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was developed in the 1950s as a sedative having only a low toxicity." | 6.42 | [New pharmacological availability of thalidomide based on experience in patients with multiple myeloma]. ( Murakami, H, 2004) |
| "The drug caused severe birth defects." | 2.58 | The changing health of Thalidomide survivors as they age: A scoping review. ( Atkin, K; Newbronner, E, 2018) |
| "Thalidomide was developed in the 1950s as a sedative having only a low toxicity." | 2.42 | [New pharmacological availability of thalidomide based on experience in patients with multiple myeloma]. ( Murakami, H, 2004) |
| "Thalidomide was later found to very effectively suppress erythema nodosum leprosum (ENL)." | 2.41 | Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. ( Clark, TE; Edom, N; Larson, J; Lindsey, LJ, 2001) |
| "Lenalidomide is a thalidomide derivative designed for reduced toxicity and increased immunomodulatory properties." | 1.42 | Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. ( Anderson, S; Mante, M; Masliah, E; Rockenstein, E; Valera, E, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Niecke, A | 1 |
| Peters, K | 1 |
| Samel, C | 1 |
| Forster, K | 1 |
| Lüngen, M | 1 |
| Pfaff, H | 1 |
| Albus, C | 1 |
| Newbronner, E | 1 |
| Atkin, K | 1 |
| Imai, K | 1 |
| Iida, T | 1 |
| Yamamoto, M | 1 |
| Komatsu, K | 1 |
| Nukui, Y | 1 |
| Yoshizawa, A | 1 |
| Valera, E | 1 |
| Mante, M | 1 |
| Anderson, S | 1 |
| Rockenstein, E | 1 |
| Masliah, E | 1 |
| LAZURE, D | 1 |
| GINGRAS, G | 1 |
| MONGEAU, M | 1 |
| MOREAULT, P | 1 |
| DUPUIS, M | 1 |
| HEBERT, B | 1 |
| CORRIVEAU, C | 1 |
| Murakami, H | 1 |
| Clark, TE | 1 |
| Edom, N | 1 |
| Larson, J | 1 |
| Lindsey, LJ | 1 |
| Fotopulos, D | 1 |
| Gordon, H | 1 |
3 reviews available for thalidomide and Behavior Disorders
| Article | Year |
|---|---|
The changing health of Thalidomide survivors as they age: A scoping review.
Topics: Aging; Comorbidity; Congenital Abnormalities; Disabled Persons; Female; Health Status; Humans; Menta | 2018 |
[New pharmacological availability of thalidomide based on experience in patients with multiple myeloma].
Topics: Animals; Blood Vessels; Clinical Trials, Phase II as Topic; Ectromelia; Erythema Nodosum; Female; Hu | 2004 |
Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.
Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Drug Labeling; Erythema Nodosum; Female; Hallucinations; H | 2001 |
7 other studies available for thalidomide and Behavior Disorders
| Article | Year |
|---|---|
Mental Disorders in People Affected by Thalidomide.
Topics: Female; Germany; Humans; Immunosuppressive Agents; Male; Mental Disorders; Middle Aged; Prevalence; | 2017 |
Psychological and mental health problems in patients with thalidomide embryopathy in Japan.
Topics: Abnormalities, Drug-Induced; Cognition; Electroencephalography; Female; Health Status; Humans; Intel | 2014 |
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Cell Line, Transformed; Cytokines; Disease Models, A | 2015 |
Habilitation of patients with congenital malformations associated with thalidomide: psychiatric and psychological aspects.
Topics: Body Image; Canada; Child; Congenital Abnormalities; Humans; Medicine; Mental Disorders; Mothers; Pa | 1963 |
CONGENITAL ANOMALIES OF THE LIMBS: II. PSYCHOLOGICAL AND EDUCATIONAL ASPECTS.
Topics: Adaptation, Psychological; Adolescent; Artificial Limbs; Biomedical Research; Body Image; Canada; Ch | 1964 |
[Huntington's chorea and chronic-progressive spinal muscular atrophy].
Topics: Adult; Anxiety; Arm; Chronic Disease; Female; Functional Laterality; Humans; Huntington Disease; Men | 1966 |
Genetical, social, and medical aspects of abortion.
Topics: Abnormalities, Drug-Induced; Abortion, Criminal; Abortion, Legal; Abortion, Therapeutic; Adolescent; | 1968 |